■LERUP SSP®

HLA-B*47 Product Insert Page 1 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: **4F9** Lot-specific Information

Olerup SSP® HLA-B*47

Product number: 101.545-06 – including *Taq* polymerase

101.545-06u – without *Taq* polymerase

Lot number: 4F9

Expiry date: 2020-03-01

Number of tests: 6 Number of wells per test: 10+1

Storage - pre-aliquoted primers: dark at -20°C

PCR Master Mix: -20°C
 Adhesive PCR seals RT
 Product Insert RT

This Product Description is only valid for Lot No. 4F9.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

Changes compared to the previous *OLERUP* SSP® HLA-B*47 Lot (3D4).

The HLA-B*47 kit is updated for new alleles to enable separation of:

- Confirmed¹ alleles as listed in the IMGT/HLA database
- Polymorphisms in exons outside of the region encoding the peptide binding domain
- Null and Alternatively expressed alleles

The format of the Worksheet has been changed.

The HLA-B*47 specificity and interpretation tables have been updated for the HLA-B alleles described since the previous *Olerup* SSP® HLA-B*47 lot was made (Lot No. 3D4). The kit design is based on IMGT/HLA database 3.28.0.

The HLA-B*47 primer set is unchanged compared to the previous *Olerup* SSP® HLA-B*47 (Lot No. 3D4).

¹As described in section Uniquely Identified Alleles.

7 Product Insert Page 2 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: 4F9 Lot-specific Information

Well **11** contains <u>Negative Control primer pairs</u>, that will amplify more than 95% of the *Olerup* SSP® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the positive control primer pair is 430 base pairs.

Length of PCR	105	200	105	80	75	80	85
product							
5'-primer ¹	164	340	440	45	45	43	36
•	5'-CAC3'	^{5'} -Agg ^{3'}	^{5'} -TTA3'	⁵ '-Tgg ³ '	⁵ '-Tgg ³ '	⁵ '-Tgg ³ '	^{5'} -TAC ^{3'}
							36
							^{5'} -TAT ^{3'}
3'-primer ²	231	2 nd I	507	59	58	57	47
	⁵ '-TgC ³ '	^{5'} -AAA ^{3'}	^{5'} -TTg ^{3'}	5'-CTC3'	^{5'} -ggC ^{3'}	5'-CTC3'	5'-ACA3'
							48
							^{5'} -gCA ^{3'}
							48
							^{5'} -gCC ^{3'}
							52
							^{5'} -TgT ^{3'}
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codonnumbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

HLA-B*47 Product Insert Page 3 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: **4F9** Lot-specific Information

PRODUCT DESCRIPTION

HLA-B*47 SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for identifying the B*47:01 to B*47:10 alleles.

PLATE LAYOUT

Each HLA-B*47 test consists of 11 PCR reactions in a 16 well cut PCR plate. Wells 12 to 16 are empty.

1	2	3	4	5	6	7	8
9	10	NC	empty	empty	empty	empty	empty

The 16 well PCR plate is marked with 'B47' in silver/gray ink.

Well No. 1 is marked with the Lot No. '4F9'.

Wells 1 to 10 – HLA-B*47 high resolution primers.

Well 11 - Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 16 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

Due to the sharing of sequence motifs between HLA-B alleles non-HLA-B*47 alleles will be amplified by some primer mixes. For further details see Specificity Table.

UNIQUELY IDENTIFIED ALLELES

All the HLA-B*47, i.e. **B*47:01 to B*47:10**, recognized by the HLA Nomenclature Committee in April 2017^{1,2} will be amplified by the primers in the HLA-B*47 SSP kit.

The HLA-B*47 kit enables separation of the confirmed HLA-B*47 alleles as listed in the IMGT/HLA database. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-B*47 alleles is listed below.

The HLA-B*47 kit also enables identification of polymorphisms in exons outside of the region encoding the peptide binding domain and of null and alternatively expressed alleles.

¹HLA-B alleles listed on the IMGT/HLA web page 2017-April-13, release 3.28.0, <u>www.ebi.ac.uk/imgt/hla</u>. ²Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page http://hla.alleles.org/alleles/deleted.html.

HLA-B*47 Product Insert Page 4 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: 4F9 Lot-specific Information

ALLELE CONFIRMATION STATUS

Allele	Status ¹	Allele	Status ¹
B*47:01:01:01	Confirmed	B*47:07	Unconfirmed
B*47:01:01:02	Unconfirmed	B*47:08	Unconfirmed
B*47:01:01:03	Confirmed	B*47:09	Unconfirmed
B*47:01:02	Unconfirmed	B*47:10	Confirmed
B*47:01:03	Unconfirmed		
B*47:02	Unconfirmed		
B*47:03	Confirmed		
B*47:04	Confirmed		
B*47:05	Confirmed		
B*47:06	Unconfirmed		

¹Allele status "confirmed" or "unconfirmed" as listed on the IMGT/HLA web page 2017-April-13, release 3.28.0, www.ebi.ac.uk/imgt/hla.

RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-B*47 homo- and heterozygotes is available upon request.

HLA-B*47 Product Insert Page 5 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: 4F9 Lot-specific Information

SPECIFICITY TABLE

HLA-B*47 SSP subtyping

Specificities and sizes of the PCR products of the 10+1 primer mixes used for HLA-B*47 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA- B*47 alleles ³	Other amplified HLA-B alleles
1	135 bp	800 bp	*47:01:01:01- 47:01:03, 47:05- 47:10	*37:06:01-37:06:02, 40:188, 44:257
2	150 bp	1070 bp	*47:01:01- 47:01:03, 47:03- 47:10	*37:06:01-37:06:02, 40:13, 40:19, 40:47, 40:96, 40:109-40:110, 40:117, 40:157, 40:188, 40:201, 40:292, 40:340, 41:46, 44:02:01:01-44:02:12, 44:02:14-44:03:36, 44:03:38-44:05:04, 44:07, 44:10-44:39, 44:41:01-44:43:02, 44:45, 44:47-44:56N, 44:58N-44:59:02, 44:61N-44:74, 44:76-44:82, 44:84:01-44:89, 44:91-44:126:02, 44:128:01-44:128:02, 44:132-44:133, 44:135-44:155, 44:157-44:200, 44:202-44:209, 44:211-44:245, 44:247-44:253, 44:255-44:269, 49:01:01-49:02, 49:04:01-49:14, 49:16-49:20, 49:22-49:25, 49:27-49:48, 51:112, 53:30, 53:39, 57:45, 57:51, 57:69, C*16:85
3	150 bp	1070 bp	*47:02	*07:133, 08:155, 15:46, 15:53, 15:106, 15:143, 15:212, 18:48, 18:107, 35:19, 35:47, 35:63, 35:154, 35:217, 35:274, 35:317, 39:69, 40:01:01-40:11:02, 40:14:01-40:16, 40:18, 40:20, 40:22N-40:40, 40:42-40:45, 40:48-40:78, 40:80-40:92, 40:94-40:95, 40:97-40:108, 40:111-40:116, 40:118N-40:136, 40:138-40:156, 40:158-40:184, 40:186:01-40:187, 40:189, 40:191-40:200, 40:202-40:206, 40:210-40:245, 40:247-40:264, 40:266-40:280, 40:282-40:288, 40:290-40:291N, 40:293-40:307, 40:309-40:339, 40:341-40:349, 40:351-40:355, 41:01:01-41:13, 41:15-41:45N, 41:47-41:52, 44:09, 44:46, 44:75, 44:90, 44:129, 44:131, 44:254, 45:01:01-45:20, 48:41, 50:01:01-50:02, 50:04-50:05, 50:07-50:20, 50:31-50:52
4	150 bp	800 bp	*47:04, 47:09 *47:08	*15:162, 40:47, 40:96, 40:110, 40:157, 40:201, 44:02:01:01-44:02:12, 44:02:14-44:02:18, 44:02:20-44:02:44, 44:02:46-44:03:36, 44:03:38-44:05:02, 44:05:04, 44:07, 44:10, 44:12-44:17, 44:19N-44:24, 44:26-44:39, 44:41:01-44:43:02, 44:45, 44:47-44:49, 44:51-44:56N, 44:58N-44:59:02, 44:61N-44:74, 44:76-44:82, 44:84:01-44:89, 44:91-44:94, 44:96-44:128:02, 44:132-44:133, 44:135-44:151, 44:153-44:155, 44:157-44:169, 44:171N-44:195N, 44:197-44:200, 44:202-44:209, 44:211-44:245, 44:247-44:253, 44:255-44:256, 44:258-44:269, 49:02, C*16:85 *08:14, 27:15, 27:28, 27:62, 27:71, A*02:298,
	ι συ υρ		47:08	^08:14, 27:15, 27:28, 27:62, 27:71, A^02:298, A*02:406

Product Insert Page 6 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: 4F9 Lot-specific Information

			<u> </u>	
5	350 bp	800 bp	*47:02-47:03	*15:06, 15:27:01, 15:27:03-15:27:04, 15:84, 15:109, 15:195, 15:327, 15:344, 15:398, 18:27, 35:23, 35:258, 40:100, 50:20, A*23:36, A*24:32
6	135 bp	1070 bp	*47:01:01:01- 47:03, 47:06- 47:10	*15:06, 15:27:01-15:27:04, 15:84, 15:109, 15:195, 15:327, 15:344, 15:398, 18:27, 82:01-82:02:02, A*23:23, C*04:180:01-04:180:02, C*14:82
7	170 bp 235 bp	1070 bp	*47:07 *47:04-47:05	*07:197, 27:01-27:05:15, 27:05:17-27:05:19, 27:05:21-27:06, 27:08-27:10, 27:12-27:13, 27:16-27:18, 27:20, 27:23, 27:26-27:27, 27:29, 27:31, 27:35-27:37, 27:39-27:42, 27:44-27:46, 27:48-27:61, 27:64N-27:69, 27:72-27:75, 27:77-27:80, 27:82-27:124, 27:126, 27:128-27:129, 27:131-27:137, 27:140-27:149, 27:151-27:152, 27:154-27:161, 37:02, 48:21, 48:26
8	195 bp	1070 bp	*47:06	
9	150 bp	800 bp	*47:09	*15:162
10	150 bp	1070 bp	*47:10	*07:197, 15:17:01:01-15:17:06, 15:168, 15:177, 15:196, 15:208, 15:216, 15:230, 15:273, 15:339, 15:342 ^w , 15:356, 15:403, 15:411, 15:423-15:424, 27:04:01-27:04:06, 27:10, 27:15, 27:18, 27:25 ^w , 27:40, 27:54, 27:63, 27:68-27:69, 27:79, 27:86, 27:92, 27:100, 27:103, 27:105, 27:108-27:109, 27:112-27:114, 27:115 ^w , 27:120, 27:147, 27:149, 50:20, 51:85, C*02:07 ^w
114	-	-	-	Negative Control

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-B*47 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁴Primer mix 11 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 430 base pairs.

'w', might be weakly amplified.

HLA-B*47 Product Insert Page 7 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: 4F9 Lot-specific Information

PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7	8	9	10
Length of spec.	135	150	150	150	350	135	170	195	150	150
PCR product				180			235			
Length of int.	800	1070	1070	800	800	1070	1070	1070	800	1070
pos. control ¹										
5'-primer(s) ²	206	206	206	206	302	368	171	368	418	418
	^{5'} -gAA ^{3'}	^{5'} -gAA ^{3'}	^{5'} -gAA ^{3'}	^{5'} -gAA ^{3'}	^{5'} -gAg ^{3'}	^{5'} -gTT ^{3'}	^{5'} -TTg ^{3'}	^{5'} -gTT ^{3'}	^{5'} -Agg ^{3'}	^{5'} -Agg ^{3'}
				418			363			
				^{5'} -Agg ^{3'}			^{5'} -AAT ^{3'}			
3'-primer(s) ³	301	317	317	309	368	463	301	523	527	527
	5' -gTC 3'	^{5'} -ggA ^{3'}	^{5'} -CgC ^{3'}	^{5'} -gTg ^{3'}	5' -CAA 3'	5' -gCT 3'	5' -gTC 3'	5' -ACC 3'	^{5'} -CCg ^{3'}	5' -CCT 3'
				527			559			
				^{5'} -CCg ^{3'}			5' -CTC 3'			
				559						
				^{5'} -CgT ^{3'}						
Well No.	1	2	3	4	5	6	7	8	9	10

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

HLA-B*47 Product Insert Page 8 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: 4F9 Lot-specific Information

CELL LINE VALIDATION SHEET HLA-B*47 SSP primer set ²														
		HLA	-B*47	SSP pr	im	er	set	t ²						
									W	ell				
					1	2	3	4	5	6	7	8	9	10
				Prod. No.:	201316801	201316802	201316803	201442704	201442705	201316806	201442707	201442708	201442709	201560910
	IHV	/C cell line ¹		B*	.,	.,	.,	.,	.,	.,	.,	- ,		.,
1	9001		*07:02		-	-	-	-	-	-	-	-	-	-
2	9280	LK707	*52:01	*73:01	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*52:01		-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*15:10	*53:01	-	-	-	-	-	-	-	-	-	-
5		KAS011	*37:01		-	-	-	-	-	-	-	-	-	-
6	9353		*39:01	*51:01	-	-	-	-	-	-	-	-	-	-
7	9020		*18:01		-	-	-	-	-	-	-	-	-	-
8	9025		*35:01		-	-	-	-	-	-	-	-	-	-
9	9026		*38:01	+	-	-	-	-	-	-	-	-	-	-
10	9107		*54:01	-			-	Ė	-		Ė	Ė		-
11	-	PITOUT	*44:03		Ε.	-	-	-			1	-	H	
12	9051		*57:01	-	-	+	-	+	-	-	-	÷	Ē	-
			*27:05		-	-		-			i.	-	_	
13		JESTHOM		*45.00	-	-	-	-	-	-	+	·	_	-
14		OLGA	*15:01	*15:20	-	-	-	-	-	-	-	-	-	-
15	9075		*40:01		-	-	+	-	-	-	-	-	-	-
16		SWEIG007	*40:02		-	-	+	-	-	-	-	-	-	-
17		CTM3953540	*08:01	*55:01	-	-	-	-	-	-	-	-	-	-
18		32367	*14:01	*56:01	-	-	-	-	-	-	-	-	-	-
19		BM16	*18:01		-	-	-	-	-	-	-	-	-	-
20	9059	SLE005	*40:01		-	_	+			-	-	-	-	-
21	9064	AMALA	*15:01		-	-	-	-	-	-	-	-	-	-
22	9056	KOSE	*35:03		-	-	-	-	-	-	-	-	-	-
23	9124	IHL	*40:02	*56:02	-	-	+	-	-	-	-	-	-	-
24	9035	JBUSH	*38:01		-	-	-	-	-	-	-	-	-	-
25	9049	IBW9	*14:02		-	-	-	-	-	-	-	-	-	-
26	9285	WT49	*58:01		-	-	-	-	-	-	-	-	-	-
27	9191	CH1007	*07:05	*51:01	-	-	-	-	-	-	-	-	-	-
28		BEL5GB	*44:02	*44:03	-	+	-	+	-	-	-	-	-	-
29	9050		*44:03	150	-	+	-	+	-	-	-	-	-	-
30	9021		*42:01		_	Ė	-	Ė	-	-	-	-	-	-
31		DUCAF	*18:01	+	-	-	-	-	-	-	-	-	Ι-	
32	9297		*41:02		-	-	+	-	-	-	-	-	-	-
33		MT14B	*40:01			-	-	<u> </u>	-	-	Ë	Ë	Ē	-
34	9104		*38:01		-	Ē	+	Ē		Ē	Ė	Ė	Ē	
					-	-	-	i.	-	_	<u> </u>	Ē	Ē	-
35		SSTO	*44:02	*05.04	-	+	-	+	-	-	-	Ŀ	<u> </u>	-
36		KT17	*15:01	*35:01	-	-	-	-	-	-	-	-	-	-
37		HHKB	*07:02	-	-	-	-	-	-	-	-	-	<u> </u>	-
38	9099		*15:01		-	-	-	-	-	-	-	-	_	-
39	9315		*08:01	*27:05	-	-	-	-	-	-	+	-	-	-
40		WHONP199	*13:02	*46:01	-	-	<u>-</u>	<u>-</u>	<u>-</u>	-	-	Ŀ	_	-
41		H0301	*14:02		-	-	-	-	-	-	-	-	<u> </u>	-
42		TAB089	*46:01		-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*46:01		-	-	-	-	-	-	-	-	-	-
44	9057	TEM	*38:01		-	-	-	-	-	-	-	-	-	-
45	9239	SHJO	*42:01	*50:01	-	-	+	-	-	-	-	-	-	-
46	9013	SCHU	*07:02		-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*51:01	İ	-	-	-	-	-	-	-	-	-	-
48		TER-ND	*35:01	*44:03	-	+	-	+	-	-	-	-	-	-
48	9303	IEK-ND	"35:U1	"44:03	-	+	_	+	_	_	-	_	_	



HLA-B*47 Product Insert Page 9 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: 4F9 Lot-specific Information

¹The provided cell line HLA specificities are retrieved from the http://www.ihwg.org/hla web site. The specificity of an individual cell line may thus be subject to change.

²The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 8 and 9 were available. The specificity of the primers in primer solution 9 were tested by separately adding one additional 5'-primer, respectively one additional 3'-primer.

In primer solution 8 it was only possible to test the 5'-primer, the 3'-primer was not possible to test.

In primer solution 7 one of the 5'-primers was not possible to test.

Additional primers in primer solutions 4 and 7 were tested by separately adding either one or two 5'-primers and/or one 3'-primer.



HLA-B*47 Product Insert Page 10 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Lot No.: 4F9 Lot-specific Information

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)





HLA-B*47 Product Insert Page 11 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Lot No.: 4F9 Lot-specific Information

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)



HLA-B*47 Product Insert Page 12 of 12

101.545-06 – including *Taq* **pol.**, IFU-01 **101.545-06u – without** *Taq* **pol.**, IFU-02

Visit <u>www.olerup.com</u> for "Instructions for Use" (IFU)

Lot No.: **4F9** Lot-specific Information

ADDRESSES:

Manufacturer:

Olerup SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-717 88 27 **Fax:** +46-8-717 88 18

E-mail: olerup-se@caredx.com **Web page:** http://www.olerup.com

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00
Fax: +43-1-710 15 00 10
E-mail: olerup-at@caredx.com
Web page: http://www.olerup.com

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1 **Fax:** 610-344-7989

E-mail: olerup-us@caredx.com
Web page: http://www.olerup.com

For information on Olerup distributors worldwide, contact Olerup GmbH.